|
US2020270306A1
|
|
Peptides and pharmaceutical compositions for treating eye diseases
|
|
TW202031675A
|
|
Peptides and pharmaceutical compositions for treating eye diseases
|
|
EP3643723A1
|
|
Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
|
|
KR20180036638A
|
|
Pharmaceutical oral capsule composite formulation of oil-soluble dutasteride and tadalafil
|
|
CN109843272A
|
|
The oral capsule compound formulation of dutasteride and Tadalafei
|
|
KR101716878B1
|
|
Pharmaceutical Capsule Composite Formulation of Dutasteride and Tadalafill Comprising Glycerol Fatty Acid Ester Derivative or Propylene Glycol Fatty Acid Ester Derivative And Method For Preparation thereof
|
|
KR101679992B1
|
|
Pharmaceutical composition comprising dutasteride and propylene glycol monolaurate and preparation method of the same
|
|
KR101679380B1
|
|
Pharmaceutical composition including dutasteride and capsule formulation comprising the same
|
|
WO2012161358A1
|
|
Pharmaceutical composition for preventing or treating attention deficit hyperactivity disorder (adhd), containing ginkgo leaf extract with enhanced terpenlactone
|
|
KR20120020575A
|
|
Dissolution rate controlled multilayered tablet for oral administration containing sarpogrelate hydrochloride and manufacturing method thereof
|
|
KR20110081535A
|
|
A pharmaceuticla composition comprising terpene lactones for preventing and treating attention deficit hyperactivity disorder
|
|
KR20090114093A
|
|
Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract
|
